Skip to main content
AI Market Summary
Loading market intelligence...

Ra Pharmaceuticals, Inc. (RARX) Stock Forecast 2025 - AI Price Prediction & Analysis


Ra Pharmaceuticals, Inc. (RARX) AI Stock Price Forecast & Investment Analysis

Ra Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading Ra Pharmaceuticals, Inc. interactive price chart and technical analysis...

Ra Pharmaceuticals, Inc. (RARX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Ra Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Ra Pharmaceuticals, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Ra Pharmaceuticals, Inc.: Ra Pharmaceuticals, Inc. operates in the Health Technology sector, establishing it as a mid-cap growth opportunity.

Ra Pharmaceuticals, Inc. (Stock Symbol: RARX) is a leading company in the Health Technology sector , specifically operating within the Pharmaceuticals: Major industry.

The organization employs approximately 89 professionals worldwide and operates under the strategic leadership of CEO Douglas A. Treco.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Ra Pharmaceuticals, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Ra Pharmaceuticals, Inc.: With $3M in annual revenue and -585.7% net margin, the company demonstrates developing profitability.

Annual Revenue: $3 million generating a -585.7% net profit margin .

Market Capitalization: $2112 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -43.8% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Ra Pharmaceuticals, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Ra Pharmaceuticals, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Ra Pharmaceuticals, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Ra Pharmaceuticals, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Ra Pharmaceuticals, Inc.: Market positioning analysis based on available financial and operational metrics.

Ra Pharmaceuticals, Inc. strategically competes in the highly dynamic Pharmaceuticals: Major marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

Ra Pharmaceuticals, Inc. (RARX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Ra Pharmaceuticals, Inc. stock analysis.

Loading Ra Pharmaceuticals, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Ra Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Ra Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Ra Pharmaceuticals, Inc.: With a P/E ratio of -20.78, the market sees the stock as potentially undervalued.

P/E Ratio -20.78x
P/B Ratio 8.68x
Market Cap $2112M
EPS $-2.31
Book Value/Share $5.53
Revenue/Share $0.07
FCF/Share $-1.74
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Ra Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Ra Pharmaceuticals, Inc.: An ROE of -43.8% indicates room for improvement in shareholder value creation.

ROE -43.8%
ROA -40.8%
ROIC -44.7%
Operating Margin -568.7%
Net Margin -585.7%
EBT Margin -586.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Ra Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Ra Pharmaceuticals, Inc.: A current ratio of 14.79 indicates strong liquidity.

Current Ratio 14.79x
Quick Ratio 14.26x
D/E Ratio 0.01x
Financial Leverage 1.08x
Interest Coverage -86.8x
Working Capital $256M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Ra Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Ra Pharmaceuticals, Inc.: Free cash flow of $-88M indicates cash challenges that need attention.

Operating Cash Flow $-87M
Free Cash Flow $-88M
Capital Spending $-1M
FCF/Sales -546.8%
CapEx/Sales 28.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Ra Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Ra Pharmaceuticals, Inc.: An asset turnover of 0.01x suggests room for improvement in asset utilization.

Asset Turnover 0.01x
Receivables Turnover 107.7x
Fixed Assets Turnover 0.5x
Days Sales Outstanding 3 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Ra Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Ra Pharmaceuticals, Inc.: With annual revenue of $3M, Ra Pharmaceuticals, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $3M
Operating Income $-107M
Net Income $-103M
R&D Expense $567M
SG&A Expense $911M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 97%
Cash & Short-term Investments 93%
Total Liabilities 8%
Accounts Receivable 0%
Dividend & Shareholder Information
Shares Outstanding 44M

Latest Ra Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Ra Pharmaceuticals, Inc. (RARX) stock price and investment outlook.

, source: Reuters

* Ra Pharmaceuticals Inc - ‍expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018 * Says no revenue recorded in three months ended June 30, 2017, ...

, source: Benzinga.com

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to ...

Ra Pharmaceuticals, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Ra Pharmaceuticals, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Ra Pharmaceuticals, Inc. Stock Forecast

How accurate are Ra Pharmaceuticals, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for RARX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Ra Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Ra Pharmaceuticals, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Ra Pharmaceuticals, Inc. a good investment in 2025?

Based on our AI analysis, Ra Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Ra Pharmaceuticals, Inc. forecasts updated?

Ra Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Ra Pharmaceuticals, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Ra Pharmaceuticals, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...